{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,13]],"date-time":"2026-05-13T17:05:28Z","timestamp":1778691928054,"version":"3.51.4"},"reference-count":69,"publisher":"Springer Science and Business Media LLC","issue":"6","license":[{"start":{"date-parts":[[2024,2,14]],"date-time":"2024-02-14T00:00:00Z","timestamp":1707868800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2024,2,14]],"date-time":"2024-02-14T00:00:00Z","timestamp":1707868800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"funder":[{"DOI":"10.13039\/501100001809","name":"NSFC","doi-asserted-by":"crossref","award":["82003872"],"award-info":[{"award-number":["82003872"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"crossref"}]},{"DOI":"10.13039\/501100004735","name":"Natural Science Foundation of\u00a0Hunan Province","doi-asserted-by":"publisher","award":["2022JJ50163"],"award-info":[{"award-number":["2022JJ50163"]}],"id":[{"id":"10.13039\/501100004735","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004735","name":"Natural Science Foundation of\u00a0Hunan Province","doi-asserted-by":"publisher","award":["2023JJ20034"],"award-info":[{"award-number":["2023JJ20034"]}],"id":[{"id":"10.13039\/501100004735","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Scientific Research Fund Project of Hunan Provincial Health Commission","award":["20201973"],"award-info":[{"award-number":["20201973"]}]},{"name":"Central government funds for guiding local scientific and Technological Development","award":["2021QZY016"],"award-info":[{"award-number":["2021QZY016"]}]},{"name":"Hunan Province Clinical Medical Technology Innovation Guidance Project","award":["2020SK51823"],"award-info":[{"award-number":["2020SK51823"]}]},{"name":"Hunan Province Clinical Medical Technology Innovation Guidance Project","award":["2021SK51828"],"award-info":[{"award-number":["2021SK51828"]}]},{"name":"Hunan Province Clinical Medical Technology Innovation Guidance Project","award":["2021SK51823"],"award-info":[{"award-number":["2021SK51823"]}]},{"name":"Hunan Provincial Clinical Medical Research Center for Drug Evaluation of major chronic diseases","award":["2023SK4040"],"award-info":[{"award-number":["2023SK4040"]}]},{"name":"The science and technology innovation Program of Hunan Province","award":["2023RC3173"],"award-info":[{"award-number":["2023RC3173"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Clin Res Cardiol"],"published-print":{"date-parts":[[2024,6]]},"DOI":"10.1007\/s00392-024-02386-6","type":"journal-article","created":{"date-parts":[[2024,2,14]],"date-time":"2024-02-14T09:02:21Z","timestamp":1707901341000},"page":"910-923","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":12,"title":["Sodium glucose cotransporter 2 inhibitors with cardiac arrhythmias in patients with type 2 diabetes mellitus: a systematic review and meta-analysis of randomized placebo-controlled trials"],"prefix":"10.1007","volume":"113","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-0594-9103","authenticated-orcid":false,"given":"Bo","family":"Xu","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Bo","family":"Kang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3037-3997","authenticated-orcid":false,"given":"Jiecan","family":"Zhou","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2024,2,14]]},"reference":[{"issue":"1","key":"2386_CR1","doi-asserted-by":"publisher","first-page":"46","DOI":"10.1016\/S2213-8587(20)30343-0","volume":"9","author":"N Marx","year":"2021","unstructured":"Marx N, Davies MJ, Grant PJ et al (2021) Guideline recommendations and the positioning of newer drugs in type 2 diabetes care. Lancet Diabetes Endocrinol 9(1):46\u201352","journal-title":"Lancet Diabetes Endocrinol"},{"issue":"9","key":"2386_CR2","doi-asserted-by":"publisher","first-page":"e722","DOI":"10.1161\/CIR.0000000000001040","volume":"145","author":"JJ Joseph","year":"2022","unstructured":"Joseph JJ, Deedwania P, Acharya T et al (2022) Comprehensive management of cardiovascular risk factors for adults with type 2 diabetes: a scientific statement from the American Heart Association. Circulation 145(9):e722\u2013e759","journal-title":"Circulation"},{"issue":"1","key":"2386_CR3","doi-asserted-by":"publisher","first-page":"94","DOI":"10.1053\/j.ajkd.2020.08.003","volume":"77","author":"KR Tuttle","year":"2021","unstructured":"Tuttle KR, Brosius FC 3rd, Cavender MA et al (2021) SGLT2 inhibition for CKD and cardiovascular disease in type 2 diabetes: report of a scientific workshop sponsored by the National Kidney Foundation. Am J Kidney Dis 77(1):94\u2013109","journal-title":"Am J Kidney Dis"},{"issue":"4","key":"2386_CR4","doi-asserted-by":"publisher","first-page":"269","DOI":"10.1016\/j.acvd.2015.01.009","volume":"108","author":"M Tadic","year":"2015","unstructured":"Tadic M, Cuspidi C (2015) Type 2 diabetes mellitus and atrial fibrillation: from mechanisms to clinical practice. Arch Cardiovasc Dis 108(4):269\u2013276","journal-title":"Arch Cardiovasc Dis"},{"issue":"4","key":"2386_CR5","doi-asserted-by":"publisher","first-page":"251","DOI":"10.1007\/s00380-006-0962-9","volume":"22","author":"MR Movahed","year":"2007","unstructured":"Movahed MR, Hashemzadeh M, Jamal M (2007) Increased prevalence of ventricular fibrillation in patients with type 2 diabetes mellitus. Heart Vessels 22(4):251\u2013253","journal-title":"Heart Vessels"},{"issue":"9","key":"2386_CR6","doi-asserted-by":"publisher","first-page":"1639","DOI":"10.1007\/s00125-008-1076-y","volume":"51","author":"HE Mulnier","year":"2008","unstructured":"Mulnier HE, Seaman HE, Raleigh VS et al (2008) Risk of myocardial infarction in men and women with type 2 diabetes in the UK: a cohort study using the General Practice Research Database. Diabetologia 51(9):1639\u20131645","journal-title":"Diabetologia"},{"issue":"3","key":"2386_CR7","doi-asserted-by":"publisher","first-page":"315","DOI":"10.1016\/j.ijcard.2005.02.050","volume":"105","author":"MR Movahed","year":"2005","unstructured":"Movahed MR, Hashemzadeh M, Jamal MM (2005) Diabetes mellitus is a strong, independent risk for atrial fibrillation and flutter in addition to other cardiovascular disease. Int J Cardiol 105(3):315\u2013318","journal-title":"Int J Cardiol"},{"issue":"8","key":"2386_CR8","doi-asserted-by":"publisher","first-page":"1107","DOI":"10.1016\/j.jacc.2019.07.020","volume":"74","author":"A Wang","year":"2019","unstructured":"Wang A, Green JB, Halperin JL, Piccini JP Sr (2019) Atrial fibrillation and diabetes mellitus: JACC review topic of the week. J Am Coll Cardiol 74(8):1107\u20131115","journal-title":"J Am Coll Cardiol"},{"issue":"4","key":"2386_CR9","doi-asserted-by":"publisher","first-page":"2611","DOI":"10.1378\/chest.128.4.2611","volume":"128","author":"MR Movahed","year":"2005","unstructured":"Movahed MR, Hashemzadeh M, Jamal MM (2005) Increased prevalence of third-degree atrioventricular block in patients with type II diabetes mellitus. Chest 128(4):2611\u20132614","journal-title":"Chest"},{"issue":"14","key":"2386_CR10","doi-asserted-by":"publisher","first-page":"e91","DOI":"10.1016\/j.jacc.2017.10.054","volume":"72","author":"SM Al-Khatib","year":"2018","unstructured":"Al-Khatib SM, Stevenson WG, Ackerman MJ et al (2018) 2017 AHA\/ACC\/HRS guideline for management of patients with ventricular arrhythmias and the prevention of sudden cardiac death: a report of the American College of Cardiology\/American Heart Association Task Force on Clinical Practice Guidelines and the Heart Rhythm Society. J Am Coll Cardiol 72(14):e91\u2013e220","journal-title":"J Am Coll Cardiol"},{"issue":"2","key":"2386_CR11","doi-asserted-by":"publisher","first-page":"217","DOI":"10.1177\/1747493019897870","volume":"16","author":"G Lippi","year":"2021","unstructured":"Lippi G, Sanchis-Gomar F, Cervellin G (2021) Global epidemiology of atrial fibrillation: an increasing epidemic and public health challenge. Int J Stroke 16(2):217\u2013221","journal-title":"Int J Stroke"},{"issue":"11","key":"2386_CR12","doi-asserted-by":"publisher","first-page":"1325","DOI":"10.1016\/j.jacc.2017.07.755","volume":"70","author":"JB Echouffo-Tcheugui","year":"2017","unstructured":"Echouffo-Tcheugui JB, Shrader P, Thomas L et al (2017) Care patterns and outcomes in atrial fibrillation patients with and without diabetes: ORBIT-AF Registry. J Am Coll Cardiol 70(11):1325\u20131335","journal-title":"J Am Coll Cardiol"},{"issue":"22","key":"2386_CR13","doi-asserted-by":"publisher","first-page":"2117","DOI":"10.1056\/NEJMoa1504720","volume":"373","author":"B Zinman","year":"2015","unstructured":"Zinman B, Wanner C, Lachin JM et al (2015) Empagliflozin, cardiovascular outcomes, and mortality in type 2 diabetes. N Engl J Med 373(22):2117\u20132128","journal-title":"N Engl J Med"},{"issue":"4","key":"2386_CR14","doi-asserted-by":"publisher","first-page":"347","DOI":"10.1056\/NEJMoa1812389","volume":"380","author":"SD Wiviott","year":"2019","unstructured":"Wiviott SD, Raz I, Bonaca MP et al (2019) Dapagliflozin and cardiovascular outcomes in type 2 diabetes. N Engl J Med 380(4):347\u2013357","journal-title":"N Engl J Med"},{"issue":"15","key":"2386_CR15","doi-asserted-by":"publisher","first-page":"1425","DOI":"10.1056\/NEJMoa2004967","volume":"383","author":"CP Cannon","year":"2020","unstructured":"Cannon CP, Pratley R, Dagogo-Jack S et al (2020) Cardiovascular outcomes with ertugliflozin in type 2 diabetes. N Engl J Med 383(15):1425\u20131435","journal-title":"N Engl J Med"},{"issue":"7","key":"2386_CR16","doi-asserted-by":"publisher","first-page":"644","DOI":"10.1056\/NEJMoa1611925","volume":"377","author":"B Neal","year":"2017","unstructured":"Neal B, Perkovic V, Mahaffey KW et al (2017) Canagliflozin and cardiovascular and renal events in type 2 diabetes. N Engl J Med 377(7):644\u2013657","journal-title":"N Engl J Med"},{"issue":"2","key":"2386_CR17","doi-asserted-by":"publisher","first-page":"210","DOI":"10.1111\/dom.13512","volume":"21","author":"DSH Bell","year":"2019","unstructured":"Bell DSH, Goncalves E (2019) Atrial fibrillation and type 2 diabetes: prevalence, etiology, pathophysiology and effect of anti-diabetic therapies. Diabetes Obes Metab 21(2):210\u2013217","journal-title":"Diabetes Obes Metab"},{"issue":"2","key":"2386_CR18","doi-asserted-by":"publisher","first-page":"14","DOI":"10.3390\/diseases8020014","volume":"8","author":"Y Saisho","year":"2020","unstructured":"Saisho Y (2020) SGLT2 inhibitors: the star in the treatment of type 2 diabetes? Diseases 8(2):14","journal-title":"Diseases"},{"key":"2386_CR19","doi-asserted-by":"publisher","first-page":"46","DOI":"10.1016\/j.amjcard.2021.08.042","volume":"160","author":"EL O'Keefe","year":"2021","unstructured":"O\u2019Keefe EL, Sturgess JE, O\u2019Keefe JH, Gupta S, Lavie CJ (2021) Prevention and treatment of atrial fibrillation via risk factor modification. Am J Cardiol 160:46\u201352","journal-title":"Am J Cardiol"},{"issue":"22","key":"2386_CR20","first-page":"00062","volume":"S1050\u20131738","author":"AA Manolis","year":"2022","unstructured":"Manolis AA, Manolis TA, Melita H, Manolis AS (2022) Sodium-glucose cotransporter type 2 inhibitors and cardiac arrhythmias. Trends Cardiovasc Med S1050\u20131738(22):00062\u201300067","journal-title":"Trends Cardiovasc Med"},{"issue":"1","key":"2386_CR21","doi-asserted-by":"publisher","first-page":"130","DOI":"10.1186\/s12933-020-01105-5","volume":"19","author":"WJ Li","year":"2020","unstructured":"Li WJ, Chen XQ, Xu LL, Li YQ, Luo BH (2020) SGLT2 inhibitors and atrial fibrillation in type 2 diabetes: a systematic review with meta-analysis of 16 randomized controlled trials. Cardiovasc Diabetol 19(1):130","journal-title":"Cardiovasc Diabetol"},{"issue":"7","key":"2386_CR22","doi-asserted-by":"publisher","first-page":"1098","DOI":"10.1016\/j.hrthm.2021.03.028","volume":"18","author":"GC Fernandes","year":"2021","unstructured":"Fernandes GC, Fernandes A, Cardoso R et al (2021) Association of SGLT2 inhibitors with arrhythmias and sudden cardiac death in patients with type 2 diabetes or heart failure: a meta-analysis of 34 randomized controlled trials. Heart Rhythm 18(7):1098\u20131105","journal-title":"Heart Rhythm"},{"issue":"15","key":"2386_CR23","doi-asserted-by":"publisher","first-page":"1227","DOI":"10.1161\/CIRCULATIONAHA.119.044183","volume":"141","author":"TA Zelniker","year":"2020","unstructured":"Zelniker TA, Bonaca MP, Furtado RHM et al (2020) Effect of dapagliflozin on atrial fibrillation in patients with type 2 diabetes mellitus: insights from the DECLARE-TIMI 58 trial. Circulation 141(15):1227\u20131234","journal-title":"Circulation"},{"issue":"36","key":"2386_CR24","doi-asserted-by":"publisher","first-page":"3727","DOI":"10.1093\/eurheartj\/ehab560","volume":"42","author":"JP Curtain","year":"2021","unstructured":"Curtain JP, Docherty KF, Jhund PS et al (2021) Effect of dapagliflozin on ventricular arrhythmias, resuscitated cardiac arrest, or sudden death in DAPA-HF. Eur Heart J 42(36):3727\u20133738","journal-title":"Eur Heart J"},{"issue":"5","key":"2386_CR25","doi-asserted-by":"publisher","first-page":"1545","DOI":"10.1161\/STROKEAHA.120.031623","volume":"52","author":"Z Zhou","year":"2021","unstructured":"Zhou Z, Jardine MJ, Li Q et al (2021) Effect of SGLT2 inhibitors on stroke and atrial fibrillation in diabetic kidney disease: results from the CREDENCE trial and meta-analysis. Stroke 52(5):1545\u20131556","journal-title":"Stroke"},{"key":"2386_CR26","doi-asserted-by":"publisher","first-page":"n71","DOI":"10.1136\/bmj.n71","volume":"372","author":"MJ Page","year":"2021","unstructured":"Page MJ, McKenzie JE, Bossuyt PM et al (2021) The PRISMA 2020 statement: an updated guideline for reporting systematic reviews. BMJ 372:n71","journal-title":"BMJ"},{"key":"2386_CR27","doi-asserted-by":"publisher","first-page":"d5928","DOI":"10.1136\/bmj.d5928","volume":"343","author":"JP Higgins","year":"2011","unstructured":"Higgins JP, Altman DG, G\u00f8tzsche PC et al (2011) The Cochrane Collaboration\u2019s tool for assessing risk of bias in randomised trials. BMJ 343:d5928","journal-title":"BMJ"},{"key":"2386_CR28","doi-asserted-by":"crossref","unstructured":"Higgins JPT, Thomas J, Chandler J, Cumpston M, Li T, Page MJ, Welch VA (eds) Cochrane Handbook for Systematic Reviews of Interventions version 6.0 (updated July 2019). Cochrane, 2019. Available from: www.training.cochrane.org\/handbook","DOI":"10.1002\/9781119536604"},{"issue":"24","key":"2386_CR29","doi-asserted-by":"publisher","first-page":"2295","DOI":"10.1056\/NEJMoa1811744","volume":"380","author":"V Perkovic","year":"2019","unstructured":"Perkovic V, Jardine MJ, Neal B et al (2019) Canagliflozin and renal outcomes in type 2 diabetes and nephropathy. N Engl J Med 380(24):2295\u20132306","journal-title":"N Engl J Med"},{"key":"2386_CR30","doi-asserted-by":"publisher","first-page":"43","DOI":"10.1186\/1741-7015-11-43","volume":"11","author":"CJ Bailey","year":"2013","unstructured":"Bailey CJ, Gross JL, Hennicken D, Iqbal N, Mansfield TA, List JF (2013) Dapagliflozin add-on to metformin in type 2 diabetes inadequately controlled with metformin: a randomized, double-blind, placebo-controlled 102-week trial. BMC Med 11:43","journal-title":"BMC Med"},{"issue":"4","key":"2386_CR31","doi-asserted-by":"publisher","first-page":"531","DOI":"10.1111\/dme.12624","volume":"32","author":"CJ Bailey","year":"2015","unstructured":"Bailey CJ, Morales Villegas EC, Woo V, Tang W, Ptaszynska A, List JF (2015) Efficacy and safety of dapagliflozin monotherapy in people with type 2 diabetes: a randomized double-blind placebo-controlled 102-week trial. Diabet Med 32(4):531\u2013541","journal-title":"Diabet Med"},{"issue":"5","key":"2386_CR32","doi-asserted-by":"publisher","first-page":"369","DOI":"10.1016\/S2213-8587(13)70208-0","volume":"2","author":"AH Barnett","year":"2014","unstructured":"Barnett AH, Mithal A, Manassie J et al (2014) Efficacy and safety of empagliflozin added to existing antidiabetes treatment in patients with type 2 diabetes and chronic kidney disease: a randomised, double-blind, placebo-controlled trial. Lancet Diabetes Endocrinol 2(5):369\u2013384","journal-title":"Lancet Diabetes Endocrinol"},{"issue":"3","key":"2386_CR33","doi-asserted-by":"publisher","first-page":"294","DOI":"10.1111\/dom.12428","volume":"17","author":"B Bode","year":"2015","unstructured":"Bode B, Stenl\u00f6f K, Harris S et al (2015) Long-term efficacy and safety of canagliflozin over 104 weeks in patients aged 55\u201380 years with type 2 diabetes. Diabetes Obes Metab 17(3):294\u2013303","journal-title":"Diabetes Obes Metab"},{"issue":"7","key":"2386_CR34","doi-asserted-by":"publisher","first-page":"1218","DOI":"10.2337\/dc14-0315","volume":"38","author":"WT Cefalu","year":"2015","unstructured":"Cefalu WT, Leiter LA, de Bruin TW, Gause-Nilsson I, Sugg J, Parikh SJ (2015) Dapagliflozin\u2019s effects on glycemia and cardiovascular risk factors in high-risk patients with type 2 diabetes: a 24-week, multicenter, randomized, double-blind, placebo-controlled study with a 28-week extension. Diabetes Care 38(7):1218\u20131227","journal-title":"Diabetes Care"},{"issue":"11","key":"2386_CR35","doi-asserted-by":"publisher","first-page":"2532","DOI":"10.1111\/dom.13413","volume":"20","author":"P Fioretto","year":"2018","unstructured":"Fioretto P, Del Prato S, Buse JB et al (2018) Efficacy and safety of dapagliflozin in patients with type 2 diabetes and moderate renal impairment (chronic kidney disease stage 3A): the DERIVE Study. Diabetes Obes Metab 20(11):2532\u20132540","journal-title":"Diabetes Obes Metab"},{"issue":"1","key":"2386_CR36","doi-asserted-by":"publisher","first-page":"49","DOI":"10.1007\/s13300-017-0337-5","volume":"9","author":"G Grunberger","year":"2018","unstructured":"Grunberger G, Camp S, Johnson J et al (2018) Ertugliflozin in patients with stage 3 chronic kidney disease and type 2 diabetes mellitus: the VERTIS RENAL randomized study. Diabetes Ther 9(1):49\u201366","journal-title":"Diabetes Ther"},{"issue":"11","key":"2386_CR37","doi-asserted-by":"publisher","first-page":"2496","DOI":"10.1111\/dom.13833","volume":"21","author":"YC Halvorsen","year":"2019","unstructured":"Halvorsen YC, Walford GA, Massaro J, Aftring RP, Freeman MW (2019) A 96-week, multinational, randomized, double-blind, parallel-group, clinical trial evaluating the safety and effectiveness of bexagliflozin as a monotherapy for adults with type 2 diabetes. Diabetes Obes Metab 21(11):2496\u20132504","journal-title":"Diabetes Obes Metab"},{"issue":"2","key":"2386_CR38","doi-asserted-by":"publisher","first-page":"147","DOI":"10.1111\/dom.12188","volume":"16","author":"CS Kovacs","year":"2014","unstructured":"Kovacs CS, Seshiah V, Swallow R et al (2014) Empagliflozin improves glycaemic and weight control as add-on therapy to pioglitazone or pioglitazone plus metformin in patients with type 2 diabetes: a 24-week, randomized, placebo-controlled trial. Diabetes Obes Metab 16(2):147\u2013158","journal-title":"Diabetes Obes Metab"},{"issue":"7","key":"2386_CR39","doi-asserted-by":"publisher","first-page":"1252","DOI":"10.1111\/jgs.12881","volume":"62","author":"LA Leiter","year":"2014","unstructured":"Leiter LA, Cefalu WT, de Bruin TW, Gause-Nilsson I, Sugg J, Parikh SJ (2014) Dapagliflozin added to usual care in individuals with type 2 diabetes mellitus with preexisting cardiovascular disease: a 24-week, multicenter, randomized, double-blind, placebo-controlled study with a 28-week extension. J Am Geriatr Soc 62(7):1252\u20131262","journal-title":"J Am Geriatr Soc"},{"issue":"11","key":"2386_CR40","doi-asserted-by":"publisher","first-page":"2009","DOI":"10.2337\/dc15-0779","volume":"38","author":"C Mathieu","year":"2015","unstructured":"Mathieu C, Ranetti AE, Li D et al (2015) Randomized, double-blind, phase 3 trial of triple therapy with dapagliflozin add-on to saxagliptin plus metformin in type 2 diabetes. Diabetes Care 38(11):2009\u20132017","journal-title":"Diabetes Care"},{"issue":"6","key":"2386_CR41","doi-asserted-by":"publisher","first-page":"429","DOI":"10.1016\/S2213-8587(19)30086-5","volume":"7","author":"C Pollock","year":"2019","unstructured":"Pollock C, Stef\u00e1nsson B, Reyner D et al (2019) Albuminuria-lowering effect of dapagliflozin alone and in combination with saxagliptin and effect of dapagliflozin and saxagliptin on glycaemic control in patients with type 2 diabetes and chronic kidney disease (DELIGHT): a randomised, double-blind, placebo-controlled trial. Lancet Diabetes Endocrinol 7(6):429\u2013441","journal-title":"Lancet Diabetes Endocrinol"},{"key":"2386_CR42","doi-asserted-by":"publisher","first-page":"154","DOI":"10.1186\/s12933-015-0314-0","volume":"14","author":"M Roden","year":"2015","unstructured":"Roden M, Merker L, Christiansen AV et al (2015) Safety, tolerability and effects on cardiometabolic risk factors of empagliflozin monotherapy in drug-na\u00efve patients with type 2 diabetes: a double-blind extension of a phase III randomized controlled trial. Cardiovasc Diabetol 14:154","journal-title":"Cardiovasc Diabetol"},{"issue":"3","key":"2386_CR43","doi-asserted-by":"publisher","first-page":"520","DOI":"10.1111\/dom.13103","volume":"20","author":"J Rosenstock","year":"2018","unstructured":"Rosenstock J, Frias J, P\u00e1ll D et al (2018) Effect of ertugliflozin on glucose control, body weight, blood pressure and bone density in type 2 diabetes mellitus inadequately controlled on metformin monotherapy (VERTIS MET). Diabetes Obes Metab 20(3):520\u2013529","journal-title":"Diabetes Obes Metab"},{"issue":"10","key":"2386_CR44","doi-asserted-by":"publisher","first-page":"936","DOI":"10.1111\/dom.12503","volume":"17","author":"J Rosenstock","year":"2015","unstructured":"Rosenstock J, Jelaska A, Zeller C et al (2015) Impact of empagliflozin added on to basal insulin in type 2 diabetes inadequately controlled on basal insulin: a 78-week randomized, double-blind, placebo-controlled trial. Diabetes Obes Metab 17(10):936\u2013948","journal-title":"Diabetes Obes Metab"},{"issue":"2","key":"2386_CR45","doi-asserted-by":"publisher","first-page":"201","DOI":"10.2337\/dc16-1347","volume":"40","author":"E S\u00f8fteland","year":"2017","unstructured":"S\u00f8fteland E, Meier JJ, Vangen B, Toorawa R, Maldonado-Lutomirsky M, Broedl UC (2017) Empagliflozin as add-on therapy in patients with type 2 diabetes inadequately controlled with linagliptin and metformin: a 24-week randomized, double-blind, parallel-group trial. Diabetes Care 40(2):201\u2013209","journal-title":"Diabetes Care"},{"issue":"1","key":"2386_CR46","doi-asserted-by":"publisher","first-page":"267","DOI":"10.1007\/s13300-014-0072-0","volume":"5","author":"K Strojek","year":"2014","unstructured":"Strojek K, Yoon KH, Hruba V, Sugg J, Langkilde AM, Parikh S (2014) Dapagliflozin added to glimepiride in patients with type 2 diabetes mellitus sustains glycemic control and weight loss over 48 weeks: a randomized, double-blind, parallel-group, placebo-controlled trial. Diabetes Ther 5(1):267\u2013283","journal-title":"Diabetes Ther"},{"issue":"21","key":"2386_CR47","doi-asserted-by":"publisher","first-page":"1693","DOI":"10.1161\/CIRCULATIONAHA.119.042375","volume":"140","author":"S Verma","year":"2019","unstructured":"Verma S, Mazer CD, Yan AT et al (2019) Effect of empagliflozin on left ventricular mass in patients with type 2 diabetes mellitus and coronary artery disease: the EMPA-HEART CardioLink-6 randomized clinical trial. Circulation 140(21):1693\u20131702","journal-title":"Circulation"},{"issue":"12","key":"2386_CR48","doi-asserted-by":"publisher","first-page":"1267","DOI":"10.1111\/ijcp.12322","volume":"67","author":"JP Wilding","year":"2013","unstructured":"Wilding JP, Charpentier G, Hollander P et al (2013) Efficacy and safety of canagliflozin in patients with type 2 diabetes mellitus inadequately controlled with metformin and sulphonylurea: a randomised trial. Int J Clin Pract 67(12):1267\u20131282","journal-title":"Int J Clin Pract"},{"issue":"6","key":"2386_CR49","doi-asserted-by":"publisher","first-page":"405","DOI":"10.7326\/0003-4819-156-6-201203200-00003","volume":"156","author":"JP Wilding","year":"2012","unstructured":"Wilding JP, Woo V, Soler NG et al (2012) Long-term efficacy of dapagliflozin in patients with type 2 diabetes mellitus receiving high doses of insulin: a randomized trial. Ann Intern Med 156(6):405\u2013415","journal-title":"Ann Intern Med"},{"issue":"10","key":"2386_CR50","doi-asserted-by":"publisher","first-page":"1016","DOI":"10.1111\/dom.12348","volume":"16","author":"JF Yale","year":"2014","unstructured":"Yale JF, Bakris G, Cariou B et al (2014) Efficacy and safety of canagliflozin over 52 weeks in patients with type 2 diabetes mellitus and chronic kidney disease. Diabetes Obes Metab 16(10):1016\u20131027","journal-title":"Diabetes Obes Metab"},{"issue":"10","key":"2386_CR51","doi-asserted-by":"publisher","first-page":"e159","DOI":"10.2337\/dc19-1177","volume":"42","author":"A Tanaka","year":"2019","unstructured":"Tanaka A, Shimabukuro M, Machii N et al (2019) Effect of empagliflozin on endothelial function in patients with type 2 diabetes and cardiovascular disease: results from the multicenter, randomized, placebo-controlled, double-blind EMBLEM trial. Diabetes Care 42(10):e159\u2013e161","journal-title":"Diabetes Care"},{"key":"2386_CR52","unstructured":"A dose finding study to assess the effect of LIK066 compared to placebo or empagliflozin in patients with type 2 diabetes mellitus and heart failure. ClinicalTrials.gov. Available from:\u00a0https:\/\/clinicaltrials.gov\/ct2\/show\/record\/NCT03152552. Accessed 20 Jul 2023"},{"key":"2386_CR53","unstructured":"Efficacy and safety of sotagliflozin versus placebo and empagliflozin in participants with type 2 diabetes mellitus who have inadequate glycemic control while taking a DPP4 inhibitor alone or with metformin (SOTA-EMPA). ClinicalTrials.gov. Available from:\u00a0https:\/\/clinicaltrials.gov\/ct2\/show\/NCT03351478.\u00a0Accessed 20 Jul 2023"},{"key":"2386_CR54","unstructured":"Safety and efficacy of bexagliflozin compared to placebo as add-on therapy to metformin in type 2 diabetes subjects. ClinicalTrials.gov. Available from:\u00a0https:\/\/clinicaltrials.gov\/ct2\/show\/NCT03259789. Accessed 20 Jul 2023"},{"key":"2386_CR55","unstructured":"Bexagliflozin Efficacy and Safety Trial (BEST). ClinicalTrials.gov. Available from:\u00a0https:\/\/clinicaltrials.gov\/ct2\/show\/NCT02558296. Accessed 20 Jul 2023"},{"issue":"1","key":"2386_CR56","doi-asserted-by":"publisher","first-page":"100","DOI":"10.1186\/s12933-021-01293-8","volume":"20","author":"HL Li","year":"2021","unstructured":"Li HL, Lip GYH, Feng Q et al (2021) Sodium-glucose cotransporter 2 inhibitors (SGLT2i) and cardiac arrhythmias: a systematic review and meta-analysis. Cardiovasc Diabetol 20(1):100","journal-title":"Cardiovasc Diabetol"},{"issue":"1","key":"2386_CR57","doi-asserted-by":"publisher","first-page":"20","DOI":"10.1093\/europace\/euab177","volume":"24","author":"D Sfairopoulos","year":"2022","unstructured":"Sfairopoulos D, Zhang N, Wang Y et al (2022) Association between sodium-glucose cotransporter-2 inhibitors and risk of sudden cardiac death or ventricular arrhythmias: a meta-analysis of randomized controlled trials. Europace 24(1):20\u201330","journal-title":"Europace"},{"issue":"5","key":"2386_CR58","doi-asserted-by":"publisher","first-page":"495","DOI":"10.1177\/2047487318755531","volume":"25","author":"MS Usman","year":"2018","unstructured":"Usman MS, Siddiqi TJ, Memon MM et al (2018) Sodium-glucose co-transporter 2 inhibitors and cardiovascular outcomes: a systematic review and meta-analysis. Eur J Prev Cardiol 25(5):495\u2013502","journal-title":"Eur J Prev Cardiol"},{"issue":"21","key":"2386_CR59","doi-asserted-by":"publisher","first-page":"1995","DOI":"10.1056\/NEJMoa1911303","volume":"381","author":"JJV McMurray","year":"2019","unstructured":"McMurray JJV, Solomon SD, Inzucchi SE et al (2019) Dapagliflozin in patients with heart failure and reduced ejection fraction. N Engl J Med 381(21):1995\u20132008","journal-title":"N Engl J Med"},{"issue":"15","key":"2386_CR60","doi-asserted-by":"publisher","first-page":"1436","DOI":"10.1056\/NEJMoa2024816","volume":"383","author":"HJL Heerspink","year":"2020","unstructured":"Heerspink HJL, Stef\u00e1nsson BV, Correa-Rotter R et al (2020) Dapagliflozin in patients with chronic kidney disease. N Engl J Med 383(15):1436\u20131446","journal-title":"N Engl J Med"},{"issue":"15","key":"2386_CR61","doi-asserted-by":"publisher","first-page":"1413","DOI":"10.1056\/NEJMoa2022190","volume":"383","author":"M Packer","year":"2020","unstructured":"Packer M, Anker SD, Butler J et al (2020) Cardiovascular and renal outcomes with empagliflozin in heart failure. N Engl J Med 383(15):1413\u20131424","journal-title":"N Engl J Med"},{"issue":"16","key":"2386_CR62","doi-asserted-by":"publisher","first-page":"1451","DOI":"10.1056\/NEJMoa2107038","volume":"385","author":"SD Anker","year":"2021","unstructured":"Anker SD, Butler J, Filippatos G et al (2021) Empagliflozin in heart failure with a preserved ejection fraction. N Engl J Med 385(16):1451\u20131461","journal-title":"N Engl J Med"},{"issue":"2","key":"2386_CR63","doi-asserted-by":"publisher","first-page":"602","DOI":"10.1111\/dom.14854","volume":"25","author":"AM Fawzy","year":"2023","unstructured":"Fawzy AM, Rivera-Caravaca JM, Underhill P, Fauchier L, Lip GYH (2023) Incident heart failure, arrhythmias and cardiovascular outcomes with sodium-glucose cotransporter 2 (SGLT2) inhibitor use in patients with diabetes: insights from a global federated electronic medical record database. Diabetes Obes Metab 25(2):602\u2013610","journal-title":"Diabetes Obes Metab"},{"issue":"9","key":"2386_CR64","doi-asserted-by":"publisher","first-page":"1025","DOI":"10.1001\/jamacardio.2017.2275","volume":"2","author":"M Packer","year":"2017","unstructured":"Packer M, Anker SD, Butler J, Filippatos G, Zannad F (2017) Effects of sodium-glucose cotransporter 2 inhibitors for the treatment of patients with heart failure: proposal of a novel mechanism of action. JAMA Cardiol 2(9):1025\u20131029","journal-title":"JAMA Cardiol"},{"issue":"1","key":"2386_CR65","doi-asserted-by":"publisher","first-page":"148","DOI":"10.1186\/s12933-020-01127-z","volume":"19","author":"W Shimizu","year":"2020","unstructured":"Shimizu W, Kubota Y, Hoshika Y et al (2020) Effects of empagliflozin versus placebo on cardiac sympathetic activity in acute myocardial infarction patients with type 2 diabetes mellitus: the EMBODY trial. Cardiovasc Diabetol 19(1):148","journal-title":"Cardiovasc Diabetol"},{"issue":"6","key":"2386_CR66","doi-asserted-by":"publisher","first-page":"516","DOI":"10.1161\/CIRCULATIONAHA.120.052186","volume":"143","author":"MMY Lee","year":"2021","unstructured":"Lee MMY, Brooksbank KJM, Wetherall K et al (2021) Effect of empagliflozin on left ventricular volumes in patients with type 2 diabetes, or prediabetes, and heart failure with reduced ejection fraction (SUGAR-DM-HF). Circulation 143(6):516\u2013525","journal-title":"Circulation"},{"issue":"1","key":"2386_CR67","doi-asserted-by":"publisher","first-page":"165","DOI":"10.1186\/s12933-019-0964-4","volume":"18","author":"Q Shao","year":"2019","unstructured":"Shao Q, Meng L, Lee S et al (2019) Empagliflozin, a sodium glucose co-transporter-2 inhibitor, alleviates atrial remodeling and improves mitochondrial function in high-fat diet\/streptozotocin-induced diabetic rats. Cardiovasc Diabetol 18(1):165","journal-title":"Cardiovasc Diabetol"},{"issue":"7","key":"2386_CR68","doi-asserted-by":"publisher","first-page":"911","DOI":"10.1007\/s00392-023-02164-w","volume":"112","author":"JH Prochaska","year":"2023","unstructured":"Prochaska JH, J\u00fcnger C, Schulz A et al (2023) Effects of empagliflozin on left ventricular diastolic function in addition to usual care in individuals with type 2 diabetes mellitus-results from the randomized, double-blind, placebo-controlled EmDia trial. Clin Res Cardiol 112(7):911\u2013922","journal-title":"Clin Res Cardiol"},{"issue":"3","key":"2386_CR69","doi-asserted-by":"publisher","first-page":"2001","DOI":"10.1016\/j.dsx.2019.04.035","volume":"13","author":"G Chawla","year":"2019","unstructured":"Chawla G, Chaudhary KK (2019) A complete review of empagliflozin: most specific and potent SGLT2 inhibitor used for the treatment of type 2 diabetes mellitus. Diabetes Metab Syndr 13(3):2001\u20132008","journal-title":"Diabetes Metab Syndr"}],"container-title":["Clinical Research in Cardiology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00392-024-02386-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00392-024-02386-6\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00392-024-02386-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,5,21]],"date-time":"2024-05-21T08:04:35Z","timestamp":1716278675000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00392-024-02386-6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,2,14]]},"references-count":69,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2024,6]]}},"alternative-id":["2386"],"URL":"https:\/\/doi.org\/10.1007\/s00392-024-02386-6","relation":{},"ISSN":["1861-0684","1861-0692"],"issn-type":[{"value":"1861-0684","type":"print"},{"value":"1861-0692","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,2,14]]},"assertion":[{"value":"8 August 2023","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"25 January 2024","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"14 February 2024","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}